Elevated expression of CD109 has been implicated in the progression of cancers including squamous cell carcinoma, glioblastoma, prostate carcinoma, basal-like breast carcinoma, and certain adenocarcinomas and sarcomas (19–24). Here, CD109 is linked to squamous cell carcinoma.